PCN342 Relationship Between The Prevalence Of Cancers In England And Wales And The Performance Of Technology Appraisals  by Hughes, R & Chawla, R
A490  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
the ASSURE project. In this preliminary analysis, the comparative cost-effective-
ness of personalised screening strategies and current practice was calculated as 
a cost-per-case-detected from a health service perspective. Uncertainty in the 
cost-effectiveness estimate is investigated using one-way sensitivity analyses 
of key parameters. Results: The incremental cost-effectiveness ratio of a three 
risk group stratification procedure in the base case was £45,617 per-case-detected. 
Influential parameters were sensitivity of mammography, recall rate, cancer 
growth parameters and accuracy of risk estimation. ConClusions: A very simple 
stratification procedure may not be cost-effective. The optimal risk stratification 
for personalised breast screening will be investigated to determine whether this 
offers improvement in cost-effectiveness.
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objeCtives: Besides being associated with a negative impact on patients’ lives 
and a low 5-year survival rate[1], stage IV (metastatic) breast cancer is accompa-
nied with high treatment costs. The objective of this research was to analyse recent 
HTA decisions on metastatic breast cancer of different national HTA bodies world-
wide and investigate reasons for variances in their decision making. Methods: 
Reimbursement decisions for metastatic breast cancer treatments across various 
national HTA bodies published between January 2013 and May 2015 were analysed. 
Factors such as variations in treatment guidelines, different disease mutations, 
specific lines of therapy or if the drug was a single or add-on treatment were not 
considered. Each HTA decision was analysed according to the following criteria: 
clinical value, survival benefit, price, ICER (where applicable), toxicity and quality 
of life. Treatments were not compared with each other, but the HTA evaluation of 
each treatment was considered across the single countries. Results: A review of 5 
breast cancer medications recently assessed independently across 9 HTA authori-
ties (6 European HTA bodies, Canada, Australia, Japan) showed that generally, 
drugs with sufficient proof of clinical value were nationally reimbursed. Positive 
reimbursement decisions for all treatments were made in Germany and France, 
while NICE and SMC only gave negative opinions. Most common reasons for non-
approvals or restrictions were “lack of cost effectiveness” and “lack of clinical 
value” in respectively 10 and 3 of the HTA submissions. ConClusions: HTA deci-
sions for metastatic breast cancer treatments differ across countries, with some 
appearing to be more willing to reimburse medications. Clinical effectiveness was 
the most important decision factor for 5 countries, whereas cost-effectiveness 
was more relevant to the remaining 4 HTA bodies. With novel medications for 
metastatic breast cancer coming to market in the next years[2], certain criteria for 
HTA assessments might need to be re-defined. [1] http://www.cancer.org/cancer/
breastcancer/detailedguide/breast-cancer-survival-by-stage [2] http://ww5.komen.
org/BreastCancer/EmergingMetasticBreastCancer.html
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objeCtives: Payers are seeking improvements in outcomes that are meaningful 
for the patient, but the preference of payers on what change can be considered 
meaningful is not well defined. Clinically relevant differences (CRDs) in outcomes 
and grading of their magnitude in oncology are being established by both European 
and American oncology organisations (European Society for Medical Oncology 
(ESMO) and American Society of Clinical Oncology (ASCO)). This indicates a transi-
tion from a focus primarily on statistical significant improvements (i.e., “is there 
a difference?”) in outcomes towards the clinical relevance of these improvements 
(i.e., “does the difference matter to patients?”). The attitude of payers towards 
CRDs in oncology outcomes is not well-understood, with little guidance around 
oncology CRDs from payers. The objective of this study is to evaluate the align-
ment between payers and clinicians in their assessment of clinical and health 
benefit of oncology products. Methods: Oncology products launched recently 
were evaluated using the approach suggested by ESMO and ASCO. For the same 
products, the payer decision was evaluated to establish the clinical and health 
benefit rating by NICE (UK), HAS (France) and G-BA (Germany). Results: Not all 
products granted market approval have been evaluated by payers. The research 
showed that where they had been evaluated, payer quantification of clinical ben-
efit differed to that recommended by oncology societies. Furthermore, clinical 
benefit assessment, particularly regarding overall survival improvement, differed 
between payers themselves. ConClusions: Oncology societies are recognising 
the need to ensure consistent assessment and representation of clinical benefit 
of new oncology products. Whilst payers often have guidance on how they assess 
benefit, this is often generic and applied across therapy areas. As a consequence, 
there still remains an inconsistent approach to evaluating clinical benefits in 
oncology between payers, which provides challenges and implications in drug 
development programmes for novel oncology therapies.
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objeCtives: Cancer is the most common cause of mortality in England and Wales. 
This study investigated whether the number of technologies assessed by NICE for 
a specific cancer reflects its prevalence in England and Wales Methods: 1-year 
elements more important to assessing value may improve these processes and 
contribute to giving a fairer access to appropriate treatments to patients.
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objeCtives: The end-of-life consideration introduced by NICE in January 2009 allows 
extension of the upper limit of the cost-effectiveness thresholds beyond £30,000 per 
QALY for therapies that are indicated in patients with a short life expectancy and for 
small patient populations, with survival benefit of at least 3 months. The aim of this 
study was to assess the impact of the end-of-life considerations on health technol-
ogy assessment (HTA) recommendations for oncology therapies. Methods: NICE 
single technology appraisals (STAs) for oncology therapies published between 2009 
and June 11, 2015 were assessed. End-of-life consideration, HTA recommendations, 
incremental cost-effectiveness ratio (ICER) values and the availability of patient access 
schemes were extracted. Results: A total of 53 STAs were identified during the study 
period and 20 appraisals/therapies met the end-of-life criteria. Maximum end-of-life 
considerations were granted in the year 2009 and 2012 (4 each), while 2013 to 2015 
recorded the minimum (2 each). Of the therapies meeting the end-of-life criteria, 13 
received positive recommendations with the ICER values ranging from £31,800 to 
£58,590. Highest percentage of positive recommendations were reported in the year 
2009 (100%), whereas no positive recommendations were recorded in 2013, which 
could be attributable to the high ICER values of the end-of-life therapies appraised in 
2013 (£40,000 to £100,000). In 2014 and 2015 each, 50% therapies (1/2) received positive 
recommendations. Of the 13 positive recommendations, 11 included patient access 
schemes by manufacturers. Unacceptably high ICER values followed by economic 
modelling issues leading to uncertain ICER values were major drivers of negative deci-
sions. ConClusions: The use of end-of-life criteria for maximizing patient access 
remains suboptimal, as fewer treatments have met the end-of-life criteria in recent 
years. Also, increasing ICER values in end-of-life cancer appraisals have resulted in 
negative decisions. Patient access schemes by manufacturers may improve patients’ 
access to novel end-of-life oncology therapies.
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objeCtives: A key challenge for successful introduction of new drugs in meta-
static breast cancer (MBC) is a positive health technology assessment (HTA) 
outcome across Europe. Thus, understanding of the MBC HTA landscape is essen-
tial. This study aims to identify key decision drivers and challenges for HTA in 
MBC. Methods: An in-depth analysis of published HTA submissions in MBC over 
the last 5 years was conducted. In total, 96 HTA reports in MBC from 9 agencies 
were identified. Based on submission type and approval status, 38 HTA assess-
ments for 8 drugs were selected for further analysis. The analysis focussed on the 
submitted data and valuation by the different agencies. Outcomes were validated 
in an HTA expert meeting. Results: Of 38 HTA assessments, 11 received a nega-
tive recommendation, 8 a positive recommendation, and 13 a positive recom-
mendation with restrictions. The remaining 6 assessments were ongoing/did not 
provide a recommendation as yet. The majority of submissions included RCTs 
with PFS as primary endpoint and OS as secondary endpoint. HRQoL was not 
provided in 13/38 cases, with criticism in 8/38 cases. Some criticism was expressed 
regarding the logistics of HRQoL collection. The weight assigned to significance 
and incremental PFS and OS differed between countries. Twenty-eight of 38 sub-
missions included a PE evaluation. The key uncertainties in economic modelling 
related to validation of OS and PFS modelling (9/28) and the incorporation of 
safety data (11/28). Unfavourable ICERs and uncertainty in economic modelling 
were key drivers for negative decisions. ConClusions: Gaining favourable HTA 
recommendation for new MBC drugs is challenging. In order to improve probability 
of successful introduction of a new MBC drug, demonstrating significant and clini-
cally meaningful incremental OS and/or PFS is key, as is providing strong HRQoL 
data. Moreover, well-validated PE model and acceptable ICERs are important to 
gain favourable HTA opinion.
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objeCtives: This study estimates the cost-effectiveness of personalised breast 
cancer screening compared to one-size-fits-all screening. Personalised breast 
cancer screening has been proposed to both improve outcomes and screening 
programme efficiency. In a personalised screening programme frequency of 
mammography is varied based on women’s estimated risk of breast cancer. The 
Adapting Breast Cancer Screening Strategy Using Personalised Risk Estimation 
(ASSURE) project is a Europe-wide programme of work investigating new tech-
nologies and strategies in personalised screening. As there is substantial uncer-
tainty at this stage about several aspects of personalised screening the objective 
of this study is to provide information on which parameters are key in determin-
ing whether or not this strategy is cost-effective. Methods: The structure of an 
economic model to assess the cost-effectiveness of personalised screening was 
developed with input from clinical experts. A preliminary proposal uses three risk 
groups with triannual, biannual and annual screening offered. The modelling tech-
nique of discrete event simulation was used to combine a natural history model 
of breast cancer, risk stratification procedures, screening processes and expected 
outcomes over a lifetime horizon. Parameters in this mathematical model were 
informed by previously published modelling studies and data gathered within 
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A491
new FIL agents will increase. If the California data reflect national trends, uptake 
may continue to be slow compared with more established biosimilar markets in 
Europe.
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freNCH PHysiCiAN seNsitivity tO AND CONsiDerAtiON Of tHe COsts Of 
CANCer treAtmeNt
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Expenses for anticancer treatment in France have grown substantially with an aver-
age annual cost increase of 17.7% between 1999 and 2009. This is due to access to 
expensive targeted therapies, higher cancer incidence rates and overall survival in 
patients with advanced disease.objeCtives: To evaluate physician opinions and 
attitudes and their evolution between 2003 and 2013 regarding the costs of anti-
cancer treatments Methods: Conducted in France biennially, the « Cancérologie » 
study measures physician opinions/attitudes on today’s relevant topics. Latest 
waves of this study included a series of questions on the cost of anticancer treat-
ments, allowing for analysis of the evolution of responses. In 2013 315 physicians 
who work in French public or private hospitals and prescribe antitumor treatments 
for solid and/or liquid cancer participate to the study. Results: In 2003, 54% of phy-
sicians considered cancer related budgetary issues ‘very important’. Over the years, 
this percentage progressively decreased until dropping to 25% in 2013. However, in 
2003, 68% predicted that the budgetary situation would deteriorate further com-
pared with 73% in 2013. The contrast between the pessimistic perceptions of the 
future and a reality which is perceived less and less problematic demonstrates the 
dual mindset of physicians who are at once: - Citizens conscious of how the growth 
of costs can only end in an impasse, - Clinicians whose prescriptions remain guided 
by therapeutic goals. Thus in 2013, 62% of physicians indicated that costs had little to 
no impact on their choice of treatment. ConClusions: New molecule availability 
will cause costs of anticancer therapies to continue to grow at the same rate seen in 
recent years. If physicians do not take greater responsibility for their prescriptions’ 
costs, the only solution would be coercive measures.
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objeCtives: In 2013, it was shown that mutations in KRAS exons 3 and 4, or NRAS 
exons 2 to 4 had a similar effect. The primary objective was to assess the practices 
in conducting RAS testing in 2014. The secondary objectives were to describe the 
evolution of the RAS testing prescription rates from 2011, the process and time 
required to obtain the results, and to analyze their impact on the therapeutic strat-
egy. Methods: FLASH-RAS is an observational retrospective French multicenter 
study. Results: 375 mCRC patients diagnosed and initiating a 1st line treat-
ment (L1) between March and June 2014 were analyzed. For 90.1% of the patients 
(IC95%= [87.1%; 93.2%]), a genotyping request for RAS biomarkers was made in L1, 
i.e. a significantly increased rate compared to 2011 (81.1% in 2011, p< 0.001). For 75% 
of the patients, the request was made before or at least one month after the diagno-
sis of the first metastases (1st M). No increase was observed in the median and mean 
times to obtain the test results between 2011 and 2014 despite the increased number 
of exons tested. ConClusions: In 2014, the rate of RAS genotyping requests has 
been increasing since 2011. For a majority of patients, the request is made before 
or at the latest one month after 1st M diagnosis. Nevertheless, for 24.5% of the 
patients, the request is made more than one month after 1st M diagnosis, which is 
not compatible with an informed treatment decision in L1.
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objeCtives: The Chronic Care Model (CCM) is an accepted framework for deliv-
ering care to patients with chronic illnesses. The Patient Assessment of Chronic 
Illness Care (PACIC) is a questionnaire designed to assess the CCM from the 
patient´s perspective, focusing on the receipt of patient centered care. Our aim 
was to document patient´s assessment of chronic illness care in short-term cancer 
survivors, through PACIC Methods: Patients with colo-rectal (CCR), breast or 
prostate cancer and who finished their treatment three years before answering 
the questionnaire were included in the study. PACIC was administered by mail 
and has 5 subscales, patient activation (PA), delivery system design (DSD), goal 
setting (GS), problem solving (PS) and follow-up coordination (FU). In addition 
there is a global score (G). Each subscale and the global are scored from 1 to 
5 with higher scores indicating patient´s perception of greater involvement in 
self- management and receipt of chronic care counseling. Data are expressed as 
mean (standard deviation). Comparison amongst location has been carried out 
through analysis of variance with Scheffé post-hoc test. PACIC has been validated 
in Spanish. Results: There were 645 patients included, 139 prostate, 339 breast 
and 167 with CCR. The mean (SD) by dimensions were: PA: 3.2 (1.4), DSD: 3.5 (1.2), 
GS: 2.6 (1.3), PS: 2.8 (1.5), FU: 2.2 (1.2) and global: 2.8 (1.2). There were statistically 
significant differences amongst cancer location in two dimensions, PS (p= 0.02) 
and FU (p = 0.002), with best scores in CCR in both cases. ConClusions: To our 
knowledge this is the first time that PACIC is used in cancer patients. Patient 
activation and delivery system design have shown the best scores and follow-up, 
a critical point the worst score although with differences; being CCR survivors 
who better have evaluated this dimension
prevalence data for 6 cancers with values ranging from < 3 to > 170 per 105were 
obtained from the GLOBOCAN database. Clinicaltrials.gov was searched for phase 3 
trials for the cancers from 2005 to 2015; the NICE website was searched for technol-
ogy appraisals concerning the cancers for the same period. Results: Breast cancer 
(BC; prevalence, 174.1 per 105) had the greatest number of phase 3 clinical trials 
(n= 333) and NICE assessments (n= 10) in the period; three assessments resulted in 
recommendations. Prostate cancer (PC), having a similar prevalence to BC (162.5 per 
105), had 60% fewer phase 3 trials (n= 133) and 50% fewer NICE assessments (n= 5), 
but also resulted in three recommendations. Multiple myeloma (MM; prevalence, 
6.2 per 105) was the subject of a disproportionately high number of phase 3 trials 
(n= 98) and NICE assessments (n= 4); three assessments resulted in recommenda-
tions. In contrast, non-Hodgkin’s lymphoma, having a higher prevalence than MM 
(15.4 per 105) was the subject of only 40 phase 3 trials and 4 NICE assessments; three 
resulted in recommendations. Myelofibrosis and pancreatic cancer, each having a 
prevalence of < 5 per 105, were the subject of 11 and 25 phase 3 trials, respectively. 
One NICE assessment was performed for an intervention for myelofibrosis and had 
a negative outcome. ConClusions: These results suggest that while the number 
of NICE assessments undertaken reflects the number of phase 3 trials performed 
in a given cancer, there is a mismatch between the number of assessments and the 
prevalence of specific cancers in the UK. Further research is warranted to investigate 
whether a similar mismatch is evident in other countries.
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objeCtives: The Dutch minister of health made reimbursement of the first new 
melanoma drug conditional on the set-up of a population-based registry and cen-
tralisation of care. This led in 2012 to well-defined quality standards and the Dutch 
Melanoma Treatment Registry (DMTR) characterised by its unique collaboration 
between all stakeholders involved in melanoma care (public and private partner-
ship). The DMTR aims to enhance real patient value by closing the gap of the 
initial uncertainty regarding the real-world value of promising drugs in everyday 
practice. Methods: The DMTR prospectively documents detailed data of all Dutch 
advanced melanoma patients regarding tumour- and patient characteristics, treat-
ment strategies, clinical, physical, social, emotional and well-being outcomes, 
resource use, informal care, and productivity losses. These data are used for bench-
marking and outcomes research to obtain insights into real-world cost-effective-
ness of treatment pathways to improve health decision making. Results: The 
richness of DMTR data facilitates the assessment of multiple outcomes includ-
ing quality of care, use of drugs, survival benefit, quality of life, costs and cost-
effectiveness. Physicians are fortnightly provided with feedback on their delivered 
quality of care; manufacturers are provided with information regarding the use 
and performance of their drugs. This greatly enhances learning regarding the 
use and outcomes of treatments. First results (stage IV: N= 1226; median follow-
up 12.8 months) show an improved survival (2012-2015: median OS 9.3 months 
[IQR:4.5-17.4], one-year survival rate 40%) compared to the period before the 
introduction of the new drugs (2003-2011: median OS 6.8 months [IQR:3.3-18.5], 
one-year survival rate 33%). ConClusions: The DMTR provides crucial informa-
tion regarding the extent to which novel treatments offer real-world value and 
whether scarce resources are spent cost-effectively in everyday practice. Its unique 
design emphasises the essential holistic view needed in cancer management and 
can be seen as blueprint for other registries aiming at improving health decision 
making.
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objeCtives: Biosimilars of filgrastim (FIL), granulocyte colony-stimulating factor 
(G-CSF), have been available in Europe since 2008. Now 2 FIL products are approved 
in the USA: tbo-filgrastim (TBO-FIL, while a biosimilar in Europe, is not techni-
cally one in the USA; approved November 2013 for a subset of FIL indications) and 
filgrastim-sndz (FIL-SNDZ, the first true US biosimilar; approved March 2015, but 
launch delayed by ongoing litigation). Our objective was to identify physician docu-
mentation and use of TBO-FIL during patient office visits. Methods: Physician 
records were extracted (1 November 2013‒18 June 2015) from RealHealthData, a 
US medical transcription database providing data within 72 hours of each visit 
to a participating provider. Records were searched for mention of TBO-FIL: “tbo-
filgrastim,” “Granix,” or “Neutroval.” Mentions of FIL (“filgrastim” or “Neupogen”) 
and PEG (“pegfilgrastim” or “Neulasta”) were also tabulated. Results: Counts 
of mentions (and number of unique prescribers) were as follows: PEG: 1864 (40); 
FIL: 431 (53); TBO-FIL: 5 (3), with > 86% from oncologists in California. TBO-FIL 
was reported, as “Granix,” for 4 patients. Prophylactic TBO-FIL was prescribed 
for 1 chemotherapy patient and as interim treatment for 2 patients with chemo-
therapy who normally received PEG. 1 patient reported taking TBO-FIL as needed 
for neutropenia symptoms. Only 1 of the 4 received TBO-FIL as their main G-CSF 
treatment. Counts will be refreshed in October 2015 and will include FIL-SNDZ 
data, if launched and available. ConClusions: Among 2300 records reporting a 
G-CSF in this snapshot of primarily Californian oncologists, only 5 mentions of 
TBO-FIL were noted in the 18 months since launch. As awareness of ‘biosimilars’ 
improves in the USA and legal barriers are overcome, it is expected that uptake of 
